CD79A and myeloid sarcoma: Although IgA-secreting cells derive from the B-cell lineage, anti-CD20 antibodies incompletely deplete gut-resident plasma cells and circulating IgA + plasmablasts.46,47 A single previous study on the relationship between ocrelizumab treatment and the gut microbiome found no significant changes in α- or β-diversity with treatment, and reported only small changes, mainly at the phylum level, in specific microbes.48 To date, no studies have examined the effect of B-cell depletion on gut microbe-IgA–coating relationships in MS.